	US 12,441,718 B2
	Selective angiotensin II compounds
Nadia Nasser Petersen, Uppsala (SE); Anders Hallberg, Uppsala (SE); Mats Larhed, Uppsala (SE); Tomas Fex, Mölndal (SE); and Bengt Ohlsson, Mölndal (SE)
Assigned to VICORE PHARMA AB, Stockholm (SE)
Filed by VICORE PHARMA AB, Stockholm (SE)
Filed on Dec. 10, 2024, as Appl. No. 18/975,881.
Application 18/975,881 is a continuation of application No. 18/577,856, previously published as PCT/GB2022/051760, filed on Jul. 8, 2022.
Claims priority of application No. 2109946 (GB), filed on Jul. 9, 2021; and application No. 2202664 (GB), filed on Feb. 25, 2022.
Prior Publication US 2025/0101010 A1, Mar. 27, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 403/12 (2006.01); A61K 31/427 (2006.01); A61K 31/497 (2006.01); A61K 31/506 (2006.01); C07D 409/14 (2006.01); C07D 417/06 (2006.01)

CPC C07D 409/14 (2013.01) [A61K 31/427 (2013.01); A61K 31/497 (2013.01); A61K 31/506 (2013.01); C07D 403/12 (2013.01); C07D 417/06 (2013.01)]

3 Claims

1. 3-(3-Fluoro-4-((2-methyl-1H-imidazol-1-yl)methyl)phenyl)-5-isobutyl-N-(pyrimidin-2-yl)thiophene-2-sulfonamide, or a pharmaceutically acceptable salt thereof.